172 related articles for article (PubMed ID: 25885592)
1. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.
Gayed BA; Gillen J; Christie A; Peña-Llopis S; Xie XJ; Yan J; Karam JA; Raj G; Sagalowsky AI; Lotan Y; Margulis V; Brugarolas J
BMC Urol; 2015 Apr; 15():24. PubMed ID: 25885592
[TBL] [Abstract][Full Text] [Related]
2. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
3. Preoperative high levels of serum vascular endothelial growth factor are a prognostic marker for poor outcome after surgical treatment of renal cell carcinoma.
Guðbrandsdottir G; Hjelle KM; Frugård J; Bostad L; Aarstad HJ; Beisland C
Scand J Urol; 2015; 49(5):388-94. PubMed ID: 25773545
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
[TBL] [Abstract][Full Text] [Related]
5. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Tumour Biol; 2001; 22(5):282-5. PubMed ID: 11553857
[TBL] [Abstract][Full Text] [Related]
6. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma.
Sato K; Tsuchiya N; Sasaki R; Shimoda N; Satoh S; Ogawa O; Kato T
Jpn J Cancer Res; 1999 Aug; 90(8):874-9. PubMed ID: 10543260
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma.
Klatte T; Böhm M; Nelius T; Filleur S; Reiher F; Allhoff EP
BJU Int; 2007 Jul; 100(1):209-14. PubMed ID: 17428240
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
Schips L; Dalpiaz O; Lipsky K; Langner C; Rehak P; Puerstner P; Pummer K; Zigeuner R
Eur Urol; 2007 Jan; 51(1):168-73; discussion 174. PubMed ID: 16844285
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma.
Jacobsen J; Rasmuson T; Grankvist K; Ljungberg B
J Urol; 2000 Jan; 163(1):343-7. PubMed ID: 10604387
[TBL] [Abstract][Full Text] [Related]
10. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
[TBL] [Abstract][Full Text] [Related]
11. Serum tissue factor as a biomarker for renal clear cell carcinoma.
Silva DD; Noronha JAP; Pinheiro da Costa BE; Zandona PCE; Carvalhal GF
Int Braz J Urol; 2018; 44(1):38-44. PubMed ID: 28727370
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of plasma and tissue S100A4 protein and mRNA levels as potential markers of metastasis and prognosis in clear cell renal cell carcinoma.
Yang H; Zhao K; Yu Q; Wang X; Song Y; Li R
J Int Med Res; 2012; 40(2):475-85. PubMed ID: 22613408
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor.
Tanimoto S; Fukumori T; El-Moula G; Shiirevnyamba A; Kinouchi S; Koizumi T; Nakanishi R; Yamamoto Y; Taue R; Yamaguchi K; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Takahashi M; Kanayama HO
J Med Invest; 2008 Feb; 55(1-2):106-11. PubMed ID: 18319552
[TBL] [Abstract][Full Text] [Related]
14. Increased transforming growth factor beta1 plasma level in patients with renal cell carcinoma: a tumor-specific marker?
Wunderlich H; Steiner T; Kosmehl H; Junker U; Reinhold D; Reichelt O; Zermann DH; Schubert J
Urol Int; 1998 Aug; 60(4):205-7. PubMed ID: 9701731
[TBL] [Abstract][Full Text] [Related]
15. [Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients].
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Urologe A; 2000 Nov; 39(6):554-6. PubMed ID: 11138278
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.
Alamdari FI; Rasmuson T; Grankvist K; Ljungberg B
Scand J Urol Nephrol; 2007; 41(1):5-9. PubMed ID: 17366095
[TBL] [Abstract][Full Text] [Related]
17. Tissue expression and plasma levels of adrenomedullin in renal cancer patients.
Michelsen J; Thiesson H; Walter S; Ottosen PD; Skøtt O; Jensen BL
Clin Sci (Lond); 2006 Jul; 111(1):61-70. PubMed ID: 16515534
[TBL] [Abstract][Full Text] [Related]
18. Increased preoperative levels of plasma fibrinogen and D dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics.
Erdem S; Amasyali AS; Aytac O; Onem K; Issever H; Sanli O
Urol Oncol; 2014 Oct; 32(7):1031-40. PubMed ID: 25027687
[TBL] [Abstract][Full Text] [Related]
19. [Predicting postoperative recurrence of renal cell carcinoma using serum vascular endothelial growth factor].
Fujita N; Okegawa T; Tambo M; Shishido T; Nutahara K; Higashihara E
Nihon Hinyokika Gakkai Zasshi; 2013 Jan; 104(1):1-5. PubMed ID: 23457926
[TBL] [Abstract][Full Text] [Related]
20. Circulating Angiopoietin-2 levels predict mortality in kidney transplant recipients: a 4-year prospective case-cohort study.
Molnar MZ; Kümpers P; Kielstein JT; Schiffer M; Czira ME; Ujszaszi A; Kovesdy CP; Mucsi I
Transpl Int; 2014 Jun; 27(6):541-52. PubMed ID: 24628855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
